Non-Hodgkins Lymphoma Treatment Market Analysis
Non-Hodgkins Lymphoma Treatment Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026
Non-Hodgkins Lymphoma (NHL) is a type of cancer that occurs due to abnormal functioning of B or T lymphocytes and leukocytes. Around 80% of the lymphomas arise in developing B cells and the remainder arise in developing T cells. This generally occurs in bone marrow, lymph nodes, spleen, blood and other organs that are part of lymphatic system. The patients suffering from non-Hodgkin’s lymphoma are observed with symptoms like fever, weight loss, swelling of lymph nodes, anorexia, fatigue and dyspnoea. Treatment of the NHL depends whether the cells are fast or slow growing and also whether it is spread in one area or different areas of the body. Treatment options for NHL include immunotherapy, chemotherapy, stem cell transplantation, targeted therapy, monoclonal antibody therapy and radiation therapy. If blood thickens in the patient due to presence of antibodies then plasmapheresis can also be carried out. Various products available for treating lymphoma include Deltasone, Adcertis, Folotyn, Adriamycin, Prednicot, Leukeran, Velcade, Thioplex and Decadron.
The launch of new drugs in the near future expected to support the growth of non-hodgkins lymphoma treatment market. For instance, a new drug Axicabtagene ciloleucel, received priority review status to get commercialize for the treatment of non-hodgkins lymphoma as a second line therapy. This drug is expected to launch in later of year 2017.
Some cellular therapies such as T cell therapy and CAR T cell therapy are also being developed where patient’s own T cells are used to attack non-Hodgkin's lymphoma cells. Also various small molecule targeted therapies such as idelalisib and ibrutinib are latest advancements for the treatment of NHL.
Non-Hodgkins lymphoma treatment market taxonomy:
On the basis of type of non-hodgkins lymphoma, the non-hodgkins lymphoma treatment market is classified into:
On the basis of end user, the non-hodgkins lymphoma treatment market is classified into:
Rituxan drug which is used to treat NHL and had been a front-line treatment regimen, though there has been an increasing rituximab resistance. To overcome this resistance, there has been various R&D practices that will create space in the market. For instance, Roche, Inc. is conducting phase IIIstudy of Gazyva/Gazyvaro in people with previously untreated with diffuse large B-cell lymphoma. . The extension of already marketed drugs such as Velcade as a front-line therapy for mantle cell lymphoma (MCL), Revlimid for maintenance therapy of diffuse large B-cell lymphoma (DLBCL) and Adcetris for CD30 T-cell lymphoma would be further contributing towards the non-hodgkins lymphoma treatment market growth. In 2016, the U.S. Government allocated US$ 5.2 billion to the National Cancer Institute (NCI) for cancer research and training purpose.
Increase in incidence of NHL will fuel the market
By geography, North America holds the major share in the market because of the high incidence rate of blood cancers in the U.S. According to Leukemia and Lymphoma Society, non-Hodgkin lymphoma is the seventh most common cancer in the U.S. and fifth in the UK. The National Cancer Institute estimated 72,580 new cases and 20,150 deaths in 2016 due to NHL in the U.S. According to the American Cancer Society, 20 cases of NHL, 6 cases of myeloma and 13 cases of leukemia were estimated per 100,000 population in 2014 in the U.S. Moreover, the organization states that, around 6 out of 10 people diagnosed with non-Hodgkin lymphoma are aged 65 and above. Also, NHL is much more common in men than in women.
Strategies implemented by competitors to drive the market:
Key players in the non-Hodgkin’s lymphoma treatment market inlcude Novartis International AG, Pharmacyclics, Inc., Bayer AG, F. Hoffmann LA Roche, Amgen, Inc., Eli Lilly and Company, Nordic Nanovector A/S and AbbVie, Inc. The prominent players are undertaking collaborative strategies for clinical research to yield new drugs which will aid them to gain competitive advantage. For instance, Novartis AG collaborated with Aduro Biotech in 2015 for clinical trial of novel immuno-oncology product such as ADU-S100 that is expected to treat non-Hodgkin’s lymphoma. Also, taking a step ahead, Roche launched a global network of immunotherapy centers named as Immunotherapy Centers of Research Excellence (imCORE) Network in 2016. This network intends to develop potential therapies for non-Hodgkin’s lymphoma by developing drugs that will simulate one’s immune system to fight the disease.